NASDAQ: EDSAEdesa Biotech Inc Stock
$1.00-0.23 (-18.7%)
Updated Mar 17, 2023
EDSA Price
$1.00
Fair Value Price
$1.68
Market Cap
$19.96M
52 Week Low
$0.76
52 Week High
$4.00
P/E
-1.18x
P/B
1.94x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$15.51M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.14
Operating Cash Flow
-$11M
Beta
0.87
Next Earnings
May 11, 2023
Ex-Dividend
N/A
Next Dividend
N/A
EDSA Overview
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EDSA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EDSA ($1.00) is undervalued by 40.75% relative to our estimate of its Fair Value price of $1.68 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
EDSA ($1.00) is significantly undervalued by 40.75% relative to our estimate of its Fair Value price of $1.68 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
EDSA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EDSA due diligence checks available for Premium users.
Be the first to know about important EDSA news, forecast changes, insider trades & much more!
EDSA News
Valuation
EDSA fair value
Fair Value of EDSA stock based on Discounted Cash Flow (DCF)
Price
$1.00
Fair Value
$1.68
Undervalued by
40.45%
EDSA ($1.00) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EDSA ($1.00) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EDSA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EDSA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.18x
Industry
16.18x
Market
21.81x
EDSA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.94x
Industry
4.75x
EDSA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EDSA's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.3M
Profit Margin
0%
EDSA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$11.7M
Liabilities
$1.4M
Debt to equity
0.14
EDSA's short-term assets ($9.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EDSA's short-term assets ($9.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EDSA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
EDSA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.8M
Investing
$0.0
Financing
$2.9M
EDSA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EDSA vs Biotech Stocks
Edesa Biotech Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.